Newbridge Financial Services Group, Inc. Fibrogen Inc Transaction History

Newbridge Financial Services Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Mar 28, 2024	SELL	$0.38 - $0.91 $11 - $27	-30 Reduced 0.32%	9,250 $8,000
Q3 2023 Oct 17, 2023	SELL	$0.79 - $2.83 $829 - $2,971	-1,050 Reduced 10.16%	9,280 $7,000
Q2 2023 Jul 21, 2023	SELL	$2.49 - $20.59 $7,980 - $65,990	-3,205 Reduced 23.68%	10,330 $27,000
Q4 2022 Jan 17, 2023	SELL	$13.27 - $17.73 $89,572 - $119,677	-6,750 Reduced 33.28%	13,535 $0
Q3 2022 Oct 13, 2022	BUY	$11.4 - $14.6 $19,950 - $25,550	1,750 Added 9.44%	20,285 $264,000
Q4 2021 Jan 19, 2022	BUY	$9.93 - $15.39 $183,754 - $284,791	18,505 Added 61683.33%	18,535 $261,000
Q1 2021 Sep 07, 2021	BUY	$31.0 - $55.72 $930 - $1,671	30 New	30 $1,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.